Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases. The gene discussed is CTSB; the disease is early-onset autosomal dominant Alzheimer disease.